<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00685516</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000596162</org_study_id>
    <secondary_id>R01CA116242</secondary_id>
    <secondary_id>P30CA016042</secondary_id>
    <secondary_id>UCLA-061109702</secondary_id>
    <nct_id>NCT00685516</nct_id>
  </id_info>
  <brief_title>Green Tea, Black Tea, or Water in Treating Patients With Prostate Cancer Undergoing Surgery</brief_title>
  <official_title>Effects of Brewed Green and Black Tea on Inflammation, Apoptosis and Oxidation in Men With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Green tea contains ingredients that may prevent or slow the growth of certain
      cancers. It is not yet known whether green tea is more effective than black tea or water in
      treating prostate cancer.

      PURPOSE: This randomized phase II trial is studying green tea to see how well it works
      compared with black tea and water in treating patients with prostate cancer undergoing
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  to determine the effect of GT and BT consumption on apoptosis (TUNEL, ratio Bax:Bcl-2),
           proliferation, oxidation, and inflammation in malignant radical prostatectomy tissue
           compared to water control using immunohistochemistry.

        -  to examine levels of tea polyphenols and methylated tea polyphenol metabolites in fresh
           frozen radical prostatectomy tissue and urine, urinary oxidative DNA damage (8OHdG) and
           serum prostate-specific antigen (PSA) levels.

      OUTLINE: This is a multicenter, randomized study. Patients are randomized to 1 of 3 treatment
      arms.

        -  Arm I: Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of
           unacceptable toxicity.

        -  Arm II: Patients receive 6 cups of water daily for 2-8 weeks in the absence of
           unacceptable toxicity.

        -  Arm III: Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the
           absence of unacceptable toxicity.

      Patients undergo radical prostatectomy.

      Blood and urine samples, as well as tissue from diagnostic biopsy and radical prostatectomy
      specimens, are obtained for laboratory correlative studies. Samples are assessed by IHC,
      high-performance liquid chromatography, or mass spectrometry for changes in prostate tumor
      grade, stage, and margin status; concentrations of total and free tea polyphenols (i.e.,
      EGCG, EC, EGC, ECG), theaflavins, and conjugated/colonic tea metabolites; biomarkers of
      prostate cancer development and progression (i.e., serum PSA, proliferation [i.e., Ki-67],
      apoptosis [i.e., TUNEL, Bax/Bcl-2 ratio], inflammation [i.e., NFkB]), and oxidative status
      (i.e., 8OhdG/dG ratio); and genotype and gene expression of metabolizing enzymes (i.e., COMT,
      UGT, and SULT). Serum samples are also assessed by ex vivo LNCaP cell culture assay for
      antiproliferative activity and by competitive chemiluminescent immunoassay for concentrations
      of PSA, IGF-1, IGFBP-3, testosterone, SHBG, and DHEA-sulfate.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2007</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Green Tea (GT) and Black Tea (BT) Consumption on Percentage of Cells With Positive Staining for Apoptosis, Proliferation, Oxidation, and Inflammation in Malignant Radical Prostatectomy Tissue Compared to Water Control Using Immunohistochemistry.</measure>
    <time_frame>6 weeks</time_frame>
    <description>To determine the effect of Green Tea and Black Tea consumption on Prostate cancer tissue by examining programmed cell death, cell proliferation, cell oxidation, and cellular inflammation in that malignant radical prostatectomy tissue compared to water control using immunohistochemistry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of Tea Polyphenols, Their Metabolites, and Colonic Metabolites in Prostate Tissue</measure>
    <time_frame>6 weeks</time_frame>
    <description>Examine levels of tea polyphenols and methylated tea polyphenol metabolites in fresh frozen radical prostatectomy tissue and urine, urinary oxidative DNA damage (8OHdG) and serum prostate-specific antigen (PSA) levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Tea Polyphenols and Methyl-metabolites in Urine After the Consumption of Green Tea (GT) and Black Tea (BT).</measure>
    <time_frame>6 weeks</time_frame>
    <description>Concentration of tea polyphenols and methyl-metabolites in urine after the consumption of GT and BT. No polyphenols were found after water consumption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate Specific Antigen (PSA) After the Consumption of Green Tea (GT) and Black Tea (BT).</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">113</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I - Green Tea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II - Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III - Decaffeinated black tea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>green tea</intervention_name>
    <description>6 cups of green tea daily for 2-8 weeks</description>
    <arm_group_label>Arm I - Green Tea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>6 cups of water daily for 2-8 weeks</description>
    <arm_group_label>Arm II - Water</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>decaffeinated black tea</intervention_name>
    <description>6 cups of decaffeinated black tea daily for 2-8 weeks</description>
    <arm_group_label>Arm III - Decaffeinated black tea</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject consents to participate in the trial.

          -  subject is 40-75 years of age and has a diagnosis of adenocarcinoma of the prostate.

          -  Scheduled to undergo radical prostatectomy.

          -  The subject agrees to stop consumption of tea or tea-containing products throughout
             the entire intervention period except for the tea provided during study intervention.

          -  The subject agrees to stop consumption of dietary or vitamin supplements (e.g.,
             lycopene, Vitamin E, selenium, genistein) or herbal supplements (e.g., saw palmetto,
             PC-SPES)

        Exclusion Criteria:

          -  history of hepatitis or liver dysfunction

          -  ongoing alcohol abuse

          -  significant medical or psychiatric conditions that would make the patient a poor
             protocol candidate

          -  prior sensitivity or allergic reaction to tea, tea products, or tea supplements

          -  allergy or sensitivity to multiple food items or nutritional supplements

          -  concurrent luteinizing hormone-releasing hormone agonists, androgen receptor blocking
             agents, or finasteride

          -  prior bilateral orchiectomy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susanne M. Henning, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - West Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D, Carpenter CL, Heber D, Aronson WJ. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate. 2015 Apr 1;75(5):550-9. doi: 10.1002/pros.22943. Epub 2014 Dec 24.</citation>
    <PMID>25545744</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2008</study_first_posted>
  <results_first_submitted>February 18, 2016</results_first_submitted>
  <results_first_submitted_qc>April 27, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 6, 2016</results_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I - Green Tea</title>
          <description>Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
green tea: 6 cups of green tea daily for 2-8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Arm II - Water</title>
          <description>Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
placebo: 6 cups of water daily for 2-8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Arm III - Decaffeinated Black Tea</title>
          <description>Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
decaffeinated black tea: 6 cups of decaffeinated black tea daily for 2-8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>93 subjects completed the intervention (Arm I, GT: 34, Arm II, control: 33, Arm III, BT: 26).</population>
      <group_list>
        <group group_id="B1">
          <title>Arm I - Green Tea</title>
          <description>Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
green tea: 6 cups of green tea daily for 2-8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Arm II - Water</title>
          <description>Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
placebo: 6 cups of water daily for 2-8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Arm III - Decaffeinated Black Tea</title>
          <description>Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
decaffeinated black tea: 6 cups of decaffeinated black tea daily for 2-8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.1" spread="6.9"/>
                    <measurement group_id="B2" value="61.8" spread="6.2"/>
                    <measurement group_id="B3" value="61.4" spread="7.4"/>
                    <measurement group_id="B4" value="61.8" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (KG)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.7" spread="12.2"/>
                    <measurement group_id="B2" value="86.6" spread="14.3"/>
                    <measurement group_id="B3" value="89.9" spread="13.4"/>
                    <measurement group_id="B4" value="87.6" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176" spread="21"/>
                    <measurement group_id="B2" value="175" spread="22"/>
                    <measurement group_id="B3" value="175" spread="22"/>
                    <measurement group_id="B4" value="175.3" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.2" spread="3.8"/>
                    <measurement group_id="B2" value="27.4" spread="4.9"/>
                    <measurement group_id="B3" value="27.4" spread="3.6"/>
                    <measurement group_id="B4" value="27.3" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Biopsy Gleason Score (percent)</title>
          <description>Gleason Score: a system of grading prostate cancer tissue based on how it looks under a microscope. Gleason scores range from 2 to 10 and indicate how likely it is that a tumor will spread. A low Gleason score means the cancer tissue is similar to normal prostate tissue and the tumor is less likely to spread; a high Gleason score means the cancer tissue is very different from normal and the tumor is more likely to spread. A score of Gleason 7 (3 + 4) is considered significantly better and the cancer less likely to spread then a Gleason score of 7 (4 + 3).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 (3+4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 (4+3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>greater than or equal to 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum prostate-specific antigen (PSA)</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="5.2"/>
                    <measurement group_id="B2" value="9.9" spread="8.5"/>
                    <measurement group_id="B3" value="9.2" spread="4.3"/>
                    <measurement group_id="B4" value="9.6" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Green Tea (GT) and Black Tea (BT) Consumption on Percentage of Cells With Positive Staining for Apoptosis, Proliferation, Oxidation, and Inflammation in Malignant Radical Prostatectomy Tissue Compared to Water Control Using Immunohistochemistry.</title>
        <description>To determine the effect of Green Tea and Black Tea consumption on Prostate cancer tissue by examining programmed cell death, cell proliferation, cell oxidation, and cellular inflammation in that malignant radical prostatectomy tissue compared to water control using immunohistochemistry.</description>
        <time_frame>6 weeks</time_frame>
        <population>subjects that completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Green Tea</title>
            <description>Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Water</title>
            <description>Placebo:patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Arm III - Decaffeinated Black Tea</title>
            <description>Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Green Tea (GT) and Black Tea (BT) Consumption on Percentage of Cells With Positive Staining for Apoptosis, Proliferation, Oxidation, and Inflammation in Malignant Radical Prostatectomy Tissue Compared to Water Control Using Immunohistochemistry.</title>
          <description>To determine the effect of Green Tea and Black Tea consumption on Prostate cancer tissue by examining programmed cell death, cell proliferation, cell oxidation, and cellular inflammation in that malignant radical prostatectomy tissue compared to water control using immunohistochemistry.</description>
          <population>subjects that completed study</population>
          <units>percent positive of total cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Staining proliferation (Ki67)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" spread="1.83"/>
                    <measurement group_id="O2" value="2.3" spread="1.55"/>
                    <measurement group_id="O3" value="4.38" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staining apoptosis Tunel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.96" spread="8.56"/>
                    <measurement group_id="O2" value="6.7" spread="9.1"/>
                    <measurement group_id="O3" value="6.57" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staining oxidative DNA Damage 8OHdG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="7.4"/>
                    <measurement group_id="O2" value="7.27" spread="10.68"/>
                    <measurement group_id="O3" value="11.23" spread="12.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staining Proliferation Bax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" spread="11"/>
                    <measurement group_id="O2" value="37.06" spread="8.71"/>
                    <measurement group_id="O3" value="37.35" spread="7.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Staining Proliferation Bcl-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.92" spread="2.97"/>
                    <measurement group_id="O2" value="5.21" spread="6.91"/>
                    <measurement group_id="O3" value="6.48" spread="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NFKB cytoplasmic staining</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.23" spread="20.46"/>
                    <measurement group_id="O2" value="22.3" spread="14.62"/>
                    <measurement group_id="O3" value="19.21" spread="14.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NFkB nuclear staining</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="1.79"/>
                    <measurement group_id="O2" value="5.13" spread="6.37"/>
                    <measurement group_id="O3" value="4.58" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Tea Polyphenols, Their Metabolites, and Colonic Metabolites in Prostate Tissue</title>
        <description>Examine levels of tea polyphenols and methylated tea polyphenol metabolites in fresh frozen radical prostatectomy tissue and urine, urinary oxidative DNA damage (8OHdG) and serum prostate-specific antigen (PSA) levels.</description>
        <time_frame>6 weeks</time_frame>
        <population>Concentration of tea polyphenols and methyl-metabolites in prostate tissue after the consumption of GT and BT. No polyphenols were found after water consumption.
(-)-epigallocatechin-3-gallate (EGCG), (-)-epicatechin-3-gallate (ECG), (-)-epigallocatechin (EGC) , (-)-epicatechin (EC), 4'-O-methylEGC (4'-MeEGC), 4&quot;-O-methylEGCG (4&quot;-OmethylEGCG).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Green Tea</title>
            <description>Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
green tea: 6 cups of green tea daily for 2-8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Water</title>
            <description>Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
placebo: 6 cups of water daily for 2-8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm III - Decaffeinated Black Tea</title>
            <description>Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
decaffeinated black tea: 6 cups of decaffeinated black tea daily for 2-8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Tea Polyphenols, Their Metabolites, and Colonic Metabolites in Prostate Tissue</title>
          <description>Examine levels of tea polyphenols and methylated tea polyphenol metabolites in fresh frozen radical prostatectomy tissue and urine, urinary oxidative DNA damage (8OHdG) and serum prostate-specific antigen (PSA) levels.</description>
          <population>Concentration of tea polyphenols and methyl-metabolites in prostate tissue after the consumption of GT and BT. No polyphenols were found after water consumption.
(-)-epigallocatechin-3-gallate (EGCG), (-)-epicatechin-3-gallate (ECG), (-)-epigallocatechin (EGC) , (-)-epicatechin (EC), 4'-O-methylEGC (4'-MeEGC), 4&quot;-O-methylEGCG (4&quot;-OmethylEGCG).</population>
          <units>(pmol/g tissue)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EGCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" spread="32.4"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ECG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="10.1"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4&quot; MeEGCG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="19.5"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Theaflavin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Tea Polyphenols and Methyl-metabolites in Urine After the Consumption of Green Tea (GT) and Black Tea (BT).</title>
        <description>Concentration of tea polyphenols and methyl-metabolites in urine after the consumption of GT and BT. No polyphenols were found after water consumption</description>
        <time_frame>6 weeks</time_frame>
        <population>Urine concentration of (-)-epigallocatechin-3-gallate (EGCG), (-)-epicatechin-3-gallate (ECG), (-)-epigallocatechin (EGC) , (-)-epicatechin (EC), 4'-O-methylEGC (4'-MeEGC), 4&quot;-O-methylEGCG (4&quot;-OmethylEGCG).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Green Tea</title>
            <description>Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
green tea: 6 cups of green tea daily for 2-8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Water</title>
            <description>Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
placebo: 6 cups of water daily for 2-8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm III - Decaffeinated Black Tea</title>
            <description>Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
decaffeinated black tea: 6 cups of decaffeinated black tea daily for 2-8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Tea Polyphenols and Methyl-metabolites in Urine After the Consumption of Green Tea (GT) and Black Tea (BT).</title>
          <description>Concentration of tea polyphenols and methyl-metabolites in urine after the consumption of GT and BT. No polyphenols were found after water consumption</description>
          <population>Urine concentration of (-)-epigallocatechin-3-gallate (EGCG), (-)-epicatechin-3-gallate (ECG), (-)-epigallocatechin (EGC) , (-)-epicatechin (EC), 4'-O-methylEGC (4'-MeEGC), 4&quot;-O-methylEGCG (4&quot;-OmethylEGCG).</population>
          <units>umol/g creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>EGC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="16"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value=".4" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="6.1"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value=".3" spread=".3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4'-MeEGC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" spread="18"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value=".2" spread=".3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Theaflavins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prostate Specific Antigen (PSA) After the Consumption of Green Tea (GT) and Black Tea (BT).</title>
        <time_frame>6 weeks</time_frame>
        <population>Pre and post blood samples unavailable for: 4 participants in Arm I (GT group), 3 participants in Arm II (control/water group) and 3 participants in Arm III (BT group).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I - Green Tea</title>
            <description>Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
green tea: 6 cups of green tea daily for 2-8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Arm II - Water</title>
            <description>Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
placebo: 6 cups of water daily for 2-8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Arm III - Decaffeinated Black Tea</title>
            <description>Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
decaffeinated black tea: 6 cups of decaffeinated black tea daily for 2-8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate Specific Antigen (PSA) After the Consumption of Green Tea (GT) and Black Tea (BT).</title>
          <population>Pre and post blood samples unavailable for: 4 participants in Arm I (GT group), 3 participants in Arm II (control/water group) and 3 participants in Arm III (BT group).</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="4.3"/>
                    <measurement group_id="O2" value="10.0" spread="9.0"/>
                    <measurement group_id="O3" value="9.6" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I - Green Tea</title>
          <description>Patients receive 6 cups of green tea daily for 2-8 weeks in the absence of unacceptable toxicity.
green tea: 6 cups of green tea daily for 2-8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Arm II - Water</title>
          <description>Patients receive 6 cups of water daily for 2-8 weeks in the absence of unacceptable toxicity.
placebo: 6 cups of water daily for 2-8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Arm III - Decaffeinated Black Tea</title>
          <description>Patients receive 6 cups of decaffeinated black tea daily for 2-8 weeks in the absence of unacceptable toxicity.
decaffeinated black tea: 6 cups of decaffeinated black tea daily for 2-8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susanne Henning, Ph.D., Principal Investigator</name_or_title>
      <organization>UCLA</organization>
      <phone>310-825-9345</phone>
      <email>shenning@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

